α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma

L. T. Chen, T. W. Liu, Y. Chao, H. S. Shiah, J. Y. Chang, S. H. Juang, S. C. Chen, T. R. Chuang, Y. H. Chin, J. Whang-Peng

研究成果: 雜誌貢獻文章同行評審

32 引文 斯高帕斯(Scopus)

摘要

Background: Radiographic measurements do not always reflect the biological response of hepatocellular carcinoma to drug therapy. Aims: To evaluate the clinical implications of tumour marker (α-fetoprotein) response in advanced hepatocellular carcinoma patients with thalidomide treatment. Patients and methods: Forty-two advanced hepatocellular carcinoma patients with baseline α-fetoprotein levels above 200 ng/mL and thalidomide therapy were included. Serum α-fetoprotein levels were measured every 4 weeks, α-fetoprotein response was defined as a 50% or greater reduction of α-fetoprotein levels for 4 or more weeks during treatment. Radiographic response was assessed by World Health Organization criteria; survivals were estimated by Kaplan-Meier method and prognostic factors were assessed by Cox's proportional hazard model. Results: With intention-to-treat analysis, radiographic response and α-fetoprotein response were obtained in 7% (three of 42, 95% confidence interval: 0-15) and 24% (10 of 42, 95% CI: 10-38) of patients, respectively. All radiographic response was observed in α-fetoprotein responders. Multivariate analyses showed α-fetoprotein response was independent prognostic factor for both progression-free survival (relative risk = 0.394, 95% CI: 0.189-0.820, P = 0.013) and overall survival (relative risk = 0.241, 95% CI: 0.096-0.606, P = 0.003), whereas radiographic response was not. Conclusion: α-fetoprotein response can more accurately reflect the biological response of advanced hepatocellular carcinoma to thalidomide therapy than radiographic response.
原文英語
頁(從 - 到)217-226
頁數10
期刊Alimentary Pharmacology and Therapeutics
22
發行號3
DOIs
出版狀態已發佈 - 八月 1 2005
對外發佈

ASJC Scopus subject areas

  • 藥學(醫學)

指紋

深入研究「α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma」主題。共同形成了獨特的指紋。

引用此